Literature DB >> 21511017

Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.

Meredith R Clark1, Hyder A Aliyar, Chang-won Lee, Julie I Jay, Kavita M Gupta, Karen M Watson, Russell J Stewart, Robert W Buckheit, Patrick F Kiser.   

Abstract

This paper describes the design, construction and characterization of the first anti-HIV drug delivery system that is triggered to release its contents in the presence of human semen. Microgel particles were synthesized with a crosslinker containing a peptide substrate for the seminal serine protease prostate specific antigen (PSA) and were loaded with the HIV-1 entry inhibitor sodium poly(styrene-4-sulfonate) (pSS). The particles were composed of N-2-hydroxyproplymethacrylamide and bis-methacrylamide functionalized peptides based on the PSA substrates GISSFYSSK and GISSQYSSK. Exposure to human seminal plasma (HSP) degraded the microgel network and triggered the release of the entrapped antiviral polymer. Particles with the crosslinker composed of the substrate GISSFYSSK showed 17 times faster degradation in seminal plasma than that of the crosslinker composed of GISSQYSSK. The microgel particles containing 1 mol% GISSFYSSK peptide crosslinker showed complete degradation in 30 h in the presence of HSP at 37°C and pSS released from the microgels within 30 min reached a concentration of 10 μg/mL, equivalent to the published IC(90) for pSS. The released pSS inactivated HIV-1 in the presence of HSP. The solid phase synthesis of the crosslinkers, preparation of the particles by inverse microemulsion polymerization, HSP-triggered release of pSS and inactivation of HIV-1 studies are described.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21511017      PMCID: PMC3109121          DOI: 10.1016/j.ijpharm.2011.04.004

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  37 in total

Review 1.  Microbicides: a new approach to preventing HIV and other sexually transmitted infections.

Authors:  Alan Stone
Journal:  Nat Rev Drug Discov       Date:  2002-12       Impact factor: 84.694

2.  Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development.

Authors:  Sarah L Goh; Niren Murthy; Mingcheng Xu; Jean M J Fréchet
Journal:  Bioconjug Chem       Date:  2004 May-Jun       Impact factor: 4.774

3.  Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.

Authors:  Bradley J Catalone; Shendra R Miller; Mary Lee Ferguson; Dan Malamud; Tina Kish-Catalone; Nina J Thakkar; Fred C Krebs; Mary K Howett; Brian Wigdahl
Journal:  Biomed Pharmacother       Date:  2005-09       Impact factor: 6.529

4.  Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-degradable hydrogel cross-linkers.

Authors:  Jason A Moss; Shula Stokols; Mark S Hixon; Fawn T Ashley; Jason Y Chang; Kim D Janda
Journal:  Biomacromolecules       Date:  2006-04       Impact factor: 6.988

5.  Microbicide trial screeches to a halt.

Authors:  Karen Honey
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques.

Authors:  Marion Ratterree; Agegnehu Gettie; Victoria Williams; Susan Malenbaum; A Robert Neurath; Cecilia Cheng-Mayer; James Blanchard
Journal:  AIDS       Date:  2005-10-14       Impact factor: 4.177

7.  Design of new and sensitive fluorogenic substrates for human kallikrein hK3 (prostate-specific antigen) derived from semenogelin sequences.

Authors:  Sophie Réhault; Michèle Brillard-Bourdet; Luc Bourgeois; Gilles Frenette; Luiz Juliano; Francis Gauthier; Thierry Moreau
Journal:  Biochim Biophys Acta       Date:  2002-04-01

8.  Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

Authors:  Samuel R Denmeade; Carsten M Jakobsen; Samuel Janssen; Saeed R Khan; Elizabeth S Garrett; Hans Lilja; S Brogger Christensen; John T Isaacs
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

Review 9.  Biology of prostate-specific antigen.

Authors:  Hans Lilja
Journal:  Urology       Date:  2003-11       Impact factor: 2.649

10.  Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.

Authors:  S R Denmeade; A Nagy; J Gao; H Lilja; A V Schally; J T Isaacs
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

View more
  4 in total

Review 1.  Methods for Generating Hydrogel Particles for Protein Delivery.

Authors:  Allen L Liu; Andrés J García
Journal:  Ann Biomed Eng       Date:  2016-05-09       Impact factor: 3.934

2.  Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.

Authors:  Tao Zhang; Chi Zhang; Vivek Agrahari; James B Murowchick; Nathan A Oyler; Bi-Botti C Youan
Journal:  Antiviral Res       Date:  2012-12-26       Impact factor: 5.970

Review 3.  Advances in HIV microbicide development.

Authors:  Joanna S Olsen; David Easterhoff; Stephen Dewhurst
Journal:  Future Med Chem       Date:  2011-12       Impact factor: 3.808

4.  Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa.

Authors:  Rachna Rastogi; Ryan S Teller; Pedro M M Mesquita; Betsy C Herold; Patrick F Kiser
Journal:  Antiviral Res       Date:  2013-08-20       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.